Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses

• Published in: Vaccine Vol. 20; no. 21; pp. 2752 - 2763
• Main Authors: Debin, Arnaud, Kravtzoff, Roger, Santiago, Jocelyn Vaz, Cazales, Laurence, Sperandio, Sandrine, Melber, Karl, Janowicz, Zbigniew, Betbeder, Didier, Moynier, Marinette
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 21.06.2002; Elsevier
• Subjects: Adjuvants, Immunologic - administration & dosage; Adjuvants, Immunologic - pharmacology; Administration, Intranasal; Animals; Antibodies, Viral - biosynthesis; Antibody Formation; beta-Galactosidase - immunology; Biological and medical sciences; Cations - immunology; Fundamental and applied biological sciences. Psychology; Hepatitis B Surface Antigens - immunology; Immunity, Cellular; Immunity, Mucosal; Immunoglobulin A - immunology; Immunoglobulin G; Immunoglobulin M; Mice; Mice, Inbred C57BL; Microbiology; Models, Animal; Mucosal and CTL responses; Plasmids - administration & dosage; Plasmids - genetics; Recombinant proteins; SMBV™ cationic nanoparticles; T-Lymphocytes, Cytotoxic - immunology; Th1 Cells - immunology; Vaccination - methods; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies; Vaccines, Synthetic - administration & dosage; Vaccines, Synthetic - immunology; Virology; Mucosal and CTL responses; Recombinant proteins; SMBV™ cationic nanoparticles; Delivery system; Immunization; Hepatitis B surface antigen; Enzyme; Nanoparticle; Rodentia; Th1 lymphocyte; Cellular immunity; Intranasal administration; Vertebrata; Local immunity; Mammalia; Mouse; Glycosidases; Hydrolases; Th2 lymphocyte; O-Glycosidases; Humoral immunity; β-Galactosidase
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/S0264-410X(02)00191-3

New cationic nanoparticles (SMBV™) were evaluated for use as a nasal vaccine delivery system for two recombinant proteins: HBsAg and β-galactosidase. Each protein was formulated with SMBV™ and intranasally administrated to non-anesthetized mice. In each model, the formulated protein induced high levels of specific serum IgG antibodies and cytotoxic T lymphocyte (CTL) responses. Moreover, specific IgA antibodies were found in nasal as well as in vaginal washes of intranasally immunized mice with the protein associated with SMBV™. In contrast, no IgG or IgA antibodies and no CTL were detected in mice immunized with free protein. The detection of a CTL response and an increase in both IgG1 and IgG2a antibodies in serum suggest that SMBV™ amplifies both Th1 and Th2 responses without modifying the Th1/Th2 profile of the immune response induced by the natural protein. These data demonstrate the high potential of SMBV™ for use as a nasal delivery system for sub-unit vaccines.